Diabetes, a Chronic Metabolic Illness is Expected to Augment the Growth Of Human Insulin Market

08-Sep-2016 | Zion Market Research

Diabetes is a metabolic syndrome in which the person body produces little insulin or no insulin leads to diabetes mellitus (type 1/ type 2). Diabetes is characterized by high blood glucose level, excess fat around the waist and abnormal cholesterol or triglyceride level either because insulin production is inadequate, or because the body's cells do not respond properly to insulin.

Type 1 diabetes is a serious illness characterized by the body’s failure to produce insulin due to the autoimmune destruction of the beta cells produced by the pancreas. Most often type 1 diabetes occurs in childhood, but this disorder can also develop in adults at the age 40. Human insulin’s and their derivatives are only used for the treatment of type 1 diabetes mellitus. Insulin is a protein hormone produced in the pancreas and utilized for the metabolism of carbohydrates and sugar. The synthesis of human insulin was done by a process which is quite similar to the fermentation process used for preparing antibiotics. This achievement may be the most important in the treatment of type 1 diabetes. This animal insulin developed and is available for human use in the 1920's. The insulin synthesis is the first laboratory production DNA technology.

Browse the full "Human Insulin Market by Product (Drug and Drug Delivery Devices) for Type 1 Diabetes, Type 2 Diabetes Application - Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 – 2021" Report with TOC at https://www.zionmarketresearch.com/report/human-insulin-market

According to the report, the global human insulin market accounted for USD 27.0 billion in 2015 and is expected to reach USD 43.6 billion by 2021, growing at a CAGR of around 8.3% between 2015 and 2021.

Globally, human insulin market is accelerated mainly due to the sudden rise in diabetic patient across the globe. Moreover, major factors which are responsible for increasing pool of diabetic population are sedentary lifestyles, obesity, the rise in geriatric populations and poor healthcare services. This factor directly contributes to the growth of human insulin market. Furthermore, advanced technology like pen device, safety pen needles available in the market for the effective delivery of insulin are also expected to fuel the growth of the global human insulin market. However, the production cost of human insulin coupled with manufacturing complexities is the major restraint for the growth of human insulin market. In addition, complicated regulatory requirements for the approval of biotechnology derived products are also expected to restraint the growth of the global human insulin market. Nonetheless, many pipeline insulin products and untapped market of Asia Pacific are major opportunities for upcoming manufacturers of global human insulin markets.

This report forecast and analyses the human insulin market on a global and regional level. This study provides the historic data of 2015 along with a forecast from 2016 to 2021 based on revenue (USD Million). The report also includes analysis of Porter’s Five Forces model for the human insulin market. In addition, the report describes several driving and restraining factors and their impact on the human insulin market. The study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate and general attractiveness.

The report provides detailed segmentation of the human insulin market based on by product, application, and region. Product segment further bifurcated into two types: drug and delivery. Application wise the market is segmented into insulin dependent diabetes mellitus (Type 1) and non-insulin dependent diabetes mellitus (Type 2).

Geographically, the human insulin market has been segmented into five regions: North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The demand for human insulin in all regions has been analyzed and forecast based on the basis of current trends for the period of six years. North America holds the largest market share of human insulin in 2015 in terms of revenue followed by Europe. This growth is attributed to high prevalence of diabetes, technological advances in effective insulin delivery and government support in this region. The human insulin market is expected to witness the highest growth in the Asia-Pacific region in the coming years due to the large pool of patients with diabetes, rising pharmaceutical industry and advance healthcare facilities in India and China.

Key market players of human insulin market include Eli Lilly, GlaxoSmithCline, Biocon, Sanofi Aventis, Julphar, Novo Nordisk, SemBioSys, Ypsomed AG and Wockhardt among others. 

This report segments the global human insulin market as follows:

Human Insulin Market: Product Segment Analysis

  • Drugs
    • Insulin Analogs and Biosimilars
    • Human Insulin Biologics
  • Drug Delivery Devices
    • Pens
    • Pen Needles
  • Syringes

Human Insulin Market: Application Analysis

  • Insulin dependent diabetes mellitus (Type 1)
  • Non-Insulin dependent diabetes mellitus (Type 2)

Human Insulin Market: Regional Analysis

  • North America
    • U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • The Middle East & Africa

Browse press release at https://www.zionmarketresearch.com/news/global-human-insulin-market

Download Brochure
Latest Published Reports

View All Published Reports